Tuesday , December 12 2017
Home / KEEP BUT DO NOT DISPLAY / Alerts / Sanofi touts promising Ph3 results for its diabetes GLP-1 drug: once-daily lixisenatide

Sanofi touts promising Ph3 results for its diabetes GLP-1 drug: once-daily lixisenatide

Sanofi touts promising Ph3 results for its diabetes GLP-1 drug: once-daily lixisenatide

See this week’s Item #6, Sanofi’s Once Daily GLP-1 Lyxumia ® Meets Primary Endpoint in Phase 3 Study.